Key result
Continuing aspirin therapy during high-risk endoscopic procedures in patients on antiplatelets resulted in a 25.0% major bleeding rate (95% CI 10.7-44.9%), leading to early study termination.
Why the study?
Does the continuation of aspirin and postoperative resumption of thienopyridine derivatives increase the risk of major bleeding complications in patients undergoing high-risk endoscopic procedures?
Cohort (n=28)
Yes
Does the continuation of aspirin and postoperative resumption of thienopyridine derivatives increase the risk of major bleeding complications in patients undergoing high-risk endoscopic procedures?
In patients on antiplatelet therapy undergoing high-risk endoscopic procedures, postoperative resumption of thienopyridine derivatives is associated with a high risk of major bleeding, whereas continuing aspirin alone may be acceptable.
High bleeding risk with aspirin continuation during high-risk endoscopy warrants caution; leaves open optimal antiplatelet strategies for randomized trials.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Ono et al. (2015) conducted a cohort in High risk of thromboembolism requiring antiplatelet agents (n=28). Continuing aspirin treatment was evaluated on rate of major bleeding complications after endoscopic procedures (95% CI 10.7-44.9). Continuing aspirin therapy during high-risk endoscopic procedures in patients on antiplatelets resulted in a 25.0% major bleeding rate (95% CI 10.7-44.9%), leading to early study termination.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: